Brief: GenFleet Therapeutics (Shanghai) Says GFH375 Granted First Breakthrough Therapy Designation In China
02/03/2026 01:27
March 2 (Reuters) - GenFleet Therapeutics (Shanghai) Inc 2595.HK: GFH375 GRANTED FIRST BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR A-KRAS G12D INHIBITOR Further company coverage: 2595.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GenFleet Therapeutics (Shanghai)
See all newsHK-listed GenFleet jumps on positive progress of cancer drug
GenFleet hits over 3-week high as cancer drug makes progress on BTD list
Brief: GenFleet Therapeutics (Shanghai) Says GFH375 Combined With Cetuximab Placed On Proposed BTD List
HK-listed GenFleet rises most in a month on repurchasing shares
Brief: GenFleet Therapeutics (Shanghai) Reports Loss Of RMB220.17 Million For Six Months